🔗 Share this article

Given that the United States undertakes unprecedented revisions to its vaccine recommendations, an unexpected name has surfaced somewhat surprisingly: Dr. Tracy Beth Høeg, a US-based sports physician and epidemiologist who initially gained attention by questioning Covid shots during the pandemic and has focused upon potential deaths following COVID-19 immunization in her recent tenure at the Food and Drug Administration.

Proposed Overhauls to Pediatric Immunization Schedule

Agency leaders had intended to reveal sweeping revisions to the childhood vaccination calendar in December, synchronizing the US with the Danish immunization schedule, it is understood – a significant shift that would put the US out of alignment with much of the world with insufficient data for public health gain. The planned update has been postponed until the coming year.

Rather than the top vaccines chief, Dr. Høeg is scheduled to present at the gathering. She was recently named interim head of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth individual to head the office this year.

A Shift at the Regulatory Body

The acting appointment could signify a closer partnership between the pharmaceutical and vaccine branches as Dr. Høeg and Prasad strengthen their influence at the regulatory agency – and it suggests a greater focus upon rolling back long-standing immunizations at the FDA.

The new acting director has repeatedly called for ending specific childhood immunization guidelines in the US so as to align more in line with Denmark, a nation with nationalized medicine and a citizenry about the size of the state of Wisconsin.

To date public appearances, she has kept her attention on vaccines – traditionally the responsibility of Prasad, director of the FDA’s Center for Biologics Evaluation and Research (CBER) – rather than pharmaceutical oversight.

Questions Over Qualifications

Dr. Høeg has no apparent experience in drug development, regulation or management, which has been standard for former leaders of the biologics center. She has worked at the FDA as a senior adviser to the agency head and the vaccine center since spring.

“She appears not to have the requisite experience” for overseeing the CDER, remarked Dr. Jonathan Howard. “She’s never run a scientific study. She lacks experience in running a major agency. She has no expertise in pharmaceutical oversight.”

Former directors of the center would “grasp legal statutes and the research of pharmaceutical innovation”, commented a former acting FDA commissioner. “Clearly, she has not acquired the kind of background that former directors who led CBER have had.”

This division has an enormous workload at the FDA, the former commissioner pointed out.

“The public just pays attention on the new drug program, but the generic program clears a multitude of off-brand pharmaceuticals. There’s a biosimilars division, non-prescription drug unit and more, and each of these need to be looked after,” she explained. “The responsibility you neglect, that is the part that I always told people is going to cause problems.”

There is also, a significant leadership element to the role, which manages in excess of 5,000 employees. “It’s a huge leadership role, if you do it right,” the former official added.

Official Statement and Controversial Programs

In response to inquiries about Høeg’s qualifications and whether this appointment signifies more teamwork among regulatory chiefs on immunizations, a spokesperson stated that the “concerns are based on inaccurate assumptions”.

“Her resume matches the functions of her role,” the official said, pointing to the period Dr. Høeg spent counseling the FDA commissioner on “medication safety and approval science, including predictive safety algorithms and immunization monitoring”.

In her interim role, Dr. Høeg inherits the commissioner’s recently launched priority voucher program, a contentious rapid medication authorization process that allegedly concerned her predecessors. “How are these therapies being selected for this expedited pathway? Who is making the decisions?” Dr. Howard asked. “There is a lot of confidentiality happening at the regulatory body right now.”

Broadly speaking, he stated, “the FDA appears to be shifting towards more relaxed oversight of most medications, with the exception of shots.”

Established History on Vaccines

Regarding immunizations, Dr. Høeg has a clearer, if concerning, past, Howard observe. She published a analysis using unverified public submissions to estimate the incidence of heart inflammation following Covid immunization. She advised the state of Florida surgeon general Joseph Ladapo, who was said to have changed statistics to imply COVID-19 vaccines are pose a greater threat than they are.

Among her “wish list” for the current federal leadership included altering rules for new vaccines and discontinuing “unnecessary” immunizations, she remarked post-election on a online show. At the FDA, Dr. Høeg has according to sources suggested excluding teenage boys from getting Covid vaccinations.

“She’s an thorough dogmatist who commences with her conclusions and works backwards to retrofit the science in a extremely misleading, fraudulent manner,” Howard said.

Taking Control and a “Push for Payback”

Høeg became part of other dissenters, {like|